{
  "trial_id": "NCT01222260",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age",
      "label": "met",
      "evidence": "64yo woman"
    },
    {
      "criterion": "Histopathology of amyloidosis or light chain deposition disease",
      "label": "met",
      "evidence": "amyloidosis (involvement of lungs, tongue, bladder, heart)"
    },
    {
      "criterion": "Demonstrate measurable disease as defined by one or more of the following:",
      "label": "met",
      "evidence": "Serum monoclonal protein \u2265 0.5 g/dL by serum electrophoresis"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
      "label": "met",
      "evidence": "malaise, weakness, and generalized body aching x 2 days"
    },
    {
      "criterion": "Patients had at least one prior regimen consisting of at least 1 cycle",
      "label": "met",
      "evidence": "Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant"
    },
    {
      "criterion": "Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Patients must meet the following laboratory criteria:",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Absolute neutrophil count (ANC) \u2265 1.5 x 10^9/L",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Hemoglobin \u2265 9 g/dl",
      "label": "met",
      "evidence": "hemodialysis for ESRD"
    },
    {
      "criterion": "Platelets \u2265 100x 10^9/L",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Calculated creatinine clearance (CrCl) greater than or equal to 30 mL/min",
      "label": "met",
      "evidence": "hemodialysis for ESRD"
    },
    {
      "criterion": "Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 2.5 x upper limit of normal (ULN)",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Serum bilirubin <1.5 x ULN",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients meeting the criteria for symptomatic MM:",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Patients with N-terminal (NT)-proBNP \u2265 1800nb/L or B-type natriuretic peptide (BNP) \u2265 400 ng/L, abnormal cardiac troponin T (cTnT) or cardiac troponin l (cTnI)",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Patient has received other investigational drugs within 14 days prior to enrollment",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01222260",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}